JP2010502719A - アルコール誘発性脳疾患の治療、予防および回復 - Google Patents

アルコール誘発性脳疾患の治療、予防および回復 Download PDF

Info

Publication number
JP2010502719A
JP2010502719A JP2009527445A JP2009527445A JP2010502719A JP 2010502719 A JP2010502719 A JP 2010502719A JP 2009527445 A JP2009527445 A JP 2009527445A JP 2009527445 A JP2009527445 A JP 2009527445A JP 2010502719 A JP2010502719 A JP 2010502719A
Authority
JP
Japan
Prior art keywords
igf
ethanol
insulin
brain
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502719A5 (https=
Inventor
ラ モンテ スザンヌ マリエ デ
ジャック レイモンド ワンズ
Original Assignee
ロード アイランド ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロード アイランド ホスピタル filed Critical ロード アイランド ホスピタル
Publication of JP2010502719A publication Critical patent/JP2010502719A/ja
Publication of JP2010502719A5 publication Critical patent/JP2010502719A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Environmental Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009527445A 2006-09-08 2007-09-10 アルコール誘発性脳疾患の治療、予防および回復 Pending JP2010502719A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298806P 2006-09-08 2006-09-08
PCT/US2007/019626 WO2008030604A2 (en) 2006-09-08 2007-09-10 Treatment, prevention, and reversal of alcohol-induced brain disease

Publications (2)

Publication Number Publication Date
JP2010502719A true JP2010502719A (ja) 2010-01-28
JP2010502719A5 JP2010502719A5 (https=) 2011-11-10

Family

ID=39157889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527445A Pending JP2010502719A (ja) 2006-09-08 2007-09-10 アルコール誘発性脳疾患の治療、予防および回復

Country Status (7)

Country Link
US (1) US9308198B2 (https=)
EP (1) EP2061442B1 (https=)
JP (1) JP2010502719A (https=)
KR (1) KR20090066289A (https=)
AU (1) AU2007292883B2 (https=)
CA (1) CA2663121C (https=)
WO (1) WO2008030604A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523718A (ja) * 2007-04-11 2010-07-15 オメロス コーポレーション 嗜癖の予防および治療のための組成物および方法
JP2013194007A (ja) * 2012-03-21 2013-09-30 Cci Corp 抗酸化ストレス剤およびその用途
JP2015522038A (ja) * 2012-07-06 2015-08-03 オメロス コーポレーション Ａｎｄｒｏｇｒａｐｈｉｓｐａｎｉｃｕｌａｔａ組成物および嗜癖の処置のための方法
US10064850B2 (en) 2007-04-11 2018-09-04 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865761B1 (en) 2012-08-07 2014-10-21 The University Of Notre Dame Du Lac Regulation of cholesterol homeostasis

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5223242A (en) 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6294559B1 (en) 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
AU5811298A (en) 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US6060515A (en) 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
BR9814087A (pt) 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
GB9824614D0 (en) 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds
US6713514B1 (en) 1999-04-19 2004-03-30 Lexicon Pharmaceuticals, Inc. PPAR-γ agonists as agents for the treatment of type II diabetes
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
ES2277842T3 (es) 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6949259B1 (en) 1999-11-11 2005-09-27 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
US6462046B2 (en) 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
WO2001087860A2 (en) 2000-05-12 2001-11-22 Ortho-Mcneil Pharmaceutical, Inc. Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
US6908908B2 (en) 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
ES2288957T3 (es) 2000-05-12 2008-02-01 Ortho-Mcneil Pharmaceutical, Inc. 4h-benzo(1.4)oxazin-3-ina biologicamente activas.
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
CA2417005A1 (en) 2000-07-20 2002-01-31 Bristol Myers Squibb Company Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
AU2001292874B2 (en) 2000-09-27 2006-06-15 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
PL366068A1 (en) 2000-10-10 2005-01-24 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents
JP2004530408A (ja) 2000-10-19 2004-10-07 ザ ジェネラル ホスピタル コーポレーション 酵素活性の画像化法
JP4350946B2 (ja) 2000-10-31 2009-10-28 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
EP1360172A1 (en) 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
ITRM20010136A1 (it) 2001-03-16 2002-09-16 Sigma Tau Ind Farmaceuti Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
US6548538B2 (en) 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
JP2002368028A (ja) 2001-06-13 2002-12-20 Nec Corp 半導体パッケージ及びその製造方法
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US6673823B2 (en) 2002-06-04 2004-01-06 Cedars-Sinai Medical Center Use of peroxisome proliferator activated receptor (PPAR)-γ ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome
CA2499380A1 (en) 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
EP1682507A1 (en) 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
ATE557013T1 (de) 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1742923B1 (en) 2004-04-28 2009-05-27 F.Hoffmann-La Roche Ag Pyrazole phenyl derivatives as ppar activators
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
EP3788877B1 (en) 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012045081; Ａｌｃｏｈｏｌ．Ｃｌｉｎ．Ｅｘｐ．Ｒｅｓ．，　２００５，　Ｖｏｌ．　２９，　Ｎｏ．　６，　Ｐ．　１０８０-１０８９ *
JPN6012045082; Ｃｅｌｌ．Ｍｏｌ．Ｌｉｆｅ　Ｓｃｉ．，　２００５，　Ｖｏｌ．　６２，　Ｐ．　１１３１-１１４５ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523718A (ja) * 2007-04-11 2010-07-15 オメロス コーポレーション 嗜癖の予防および治療のための組成物および方法
US10064850B2 (en) 2007-04-11 2018-09-04 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
JP2013194007A (ja) * 2012-03-21 2013-09-30 Cci Corp 抗酸化ストレス剤およびその用途
JP2015522038A (ja) * 2012-07-06 2015-08-03 オメロス コーポレーション Ａｎｄｒｏｇｒａｐｈｉｓｐａｎｉｃｕｌａｔａ組成物および嗜癖の処置のための方法

Also Published As

Publication number Publication date
WO2008030604A3 (en) 2008-06-26
KR20090066289A (ko) 2009-06-23
AU2007292883B2 (en) 2013-09-05
WO2008030604A2 (en) 2008-03-13
EP2061442A4 (en) 2009-11-11
EP2061442B1 (en) 2016-08-31
AU2007292883A1 (en) 2008-03-13
US20100055037A1 (en) 2010-03-04
US9308198B2 (en) 2016-04-12
CA2663121C (en) 2016-01-19
CA2663121A1 (en) 2008-03-13
EP2061442A2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
Soscia et al. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain
EP2001503B1 (en) Diagnosis and treatment of alzheimer's disease
Cohen et al. Insulin and insulin‐like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model
Guan et al. Maslinic acid, a natural inhibitor of glycogen phosphorylase, reduces cerebral ischemic injury in hyperglycemic rats by GLT‐1 up‐regulation
Vásquez et al. Role of adenosine transport in gestational diabetes‐induced l‐arginine transport and nitric oxide synthesis in human umbilical vein endothelium
CN110891558A (zh) 使用芬氟拉明治疗多泽综合征的方法
CN109475572A (zh) 用于增强肝再生的方法
JP2010502719A (ja) アルコール誘発性脳疾患の治療、予防および回復
EP1817050B1 (en) Diagnosis and treatment of alzheimer's disease
Liu et al. Metformin induces pyroptosis in leptin receptor-defective hepatocytes via overactivation of the AMPK axis
KR101922515B1 (ko) 알코올 유발성 간 질환의 치료, 예방 및 역행
Nehra et al. A comparative study of efficacy and safety of myo-inositol versus metformin in polycystic ovarian syndrome in women
KR101352932B1 (ko) Ｐｒｘ3 를 표적으로 하는 스트레스 장애 치료제 및 이의 스크리닝 방법
US20230142111A1 (en) Compositions and methods for the treatment of pervasive development disorders
Salazar The interacting neuroendocrine network in stress-inducing mood disorders
Qiu et al. Osimertinib activates TFEB to trigger hepatocyte cytoplasmic vacuolation-associated cell death
Xu et al. Nicotine modulates expression of dynamin 1 in rat brain and SH-SY5Y cells
TW202510853A (zh) 使用賽洛西賓(psilocybin)之組合療法
US20200306285A1 (en) Methods for treating cancer using purine analogs by depleting intracellular atp
WO2020154716A1 (en) Compositions and methods for treating prostate cancer
Lund Regulation of the GABA (A) receptor alpha1 subunit in an animal model of temporal lobe epilepsy
Schleifer The role of estrogen in the mood-lowering effects of acute tryptophan depletion in postmenopausal women

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141017

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526